Decoy Biosystems completed the merger with Intec Pharma.

Decoy Biosystems, a privately-held, preclinical-stage biotechnology company, completed the merger with Intec Pharma, a drug development company. Financial terms were not disclosed. "This transformative transaction provides Intec with a robust clinical pipeline based on a novel immunotherapy platform and gives Intec entrée into the exciting area of immuno-oncology," Jeffrey A. Meckler, Intec Pharma Vice Chairman and CEO.